Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 135

1.

Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors.

Cheng YJ, Meng CT, Ying HY, Zhou JF, Yan XY, Gao X, Zhou N, Bai CM.

Medicine (Baltimore). 2018 Nov;97(45):e12750. doi: 10.1097/MD.0000000000012750.

2.

Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer.

Ma SJ, Prezzano KM, Hermann GM, Singh AK.

Radiat Oncol. 2018 Nov 6;13(1):214. doi: 10.1186/s13014-018-1158-z.

3.

First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.

Gulhati P, Prakash L, Katz MHG, Wang X, Javle M, Shroff R, Fogelman D, Lee JE, Tzeng CD, Lee JH, Weston B, Tamm E, Bhosale P, Koay EJ, Maitra A, Wang H, Wolff RA, Varadhachary GR.

Ann Surg Oncol. 2018 Oct 15. doi: 10.1245/s10434-018-6807-9. [Epub ahead of print]

PMID:
30324485
4.

Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost-intensity modulated radiotherapy with and without induction chemotherapy for locally advanced pancreatic cancer.

Oh ES, Kim TH, Woo SM, Lee WJ, Lee JH, Youn SH, Han SS, Park SJ, Kim DY.

Radiat Oncol J. 2018 Sep;36(3):200-209. doi: 10.3857/roj.2018.00073. Epub 2018 Sep 30.

5.

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.

Suker M, Nuyttens JJ, Groot Koerkamp B, Eskens FALM, van Eijck CHJ.

J Surg Oncol. 2018 Nov;118(6):1021-1026. doi: 10.1002/jso.25233. Epub 2018 Sep 27.

PMID:
30259526
6.

Conversion surgery for an initially unresectable, locally advanced pancreatic cancer after induction chemotherapy and carbon-ion radiotherapy: a case report.

Fujishiro T, Mashiko T, Masuoka Y, Yamada M, Furukawa D, Yazawa N, Kawashima Y, Ogawa M, Hirabayashi K, Nakagohri T.

Surg Case Rep. 2018 Sep 10;4(1):112. doi: 10.1186/s40792-018-0522-4.

7.

Intensification of induction chemotherapy before consolidation chemoradiotherapy improves progression-free survival and time without treatment in patients with locally advanced pancreatic cancers.

Williet N, Di Bernardo T, Vernet C, Roche LS, Muron T, Roblin X, Magne N, Phelip JM.

Oncotarget. 2018 Aug 10;9(62):31999-32009. doi: 10.18632/oncotarget.25877. eCollection 2018 Aug 10.

8.

The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma.

Huang KW, Yang PC, Pua U, Kim MD, Li SP, Qiu YD, Song TQ, Liang PC.

J Surg Oncol. 2018 Jul;118(1):31-36. doi: 10.1002/jso.25110. Epub 2018 Jun 7.

PMID:
29878378
9.

Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is the standard while surgery is uncommon.

Ramaswamy A, Jandyal S, Ostwal V, Engineer R, Lewis S, Bose S, Pande N, Shrikhande SV.

Indian J Cancer. 2017 Jul-Sep;54(3):530-534. doi: 10.4103/ijc.IJC_377_17.

10.

Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer.

Zhu X, Shi D, Li F, Ju X, Cao Y, Shen Y, Cao F, Qing S, Fang F, Jia Z, Zhang H.

Cancer Med. 2018 May 17. doi: 10.1002/cam4.1553. [Epub ahead of print]

11.

Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery.

Mazzola R, Fersino S, Aiello D, Gregucci F, Tebano U, Corradini S, Di Paola G, Cirillo M, Tondulli L, Ruffo G, Ruggieri R, Alongi F.

Strahlenther Onkol. 2018 Sep;194(9):835-842. doi: 10.1007/s00066-018-1306-2. Epub 2018 Apr 25.

PMID:
29696321
12.

Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.

Marchegiani G, Todaro V, Boninsegna E, Negrelli R, Sureka B, Bonamini D, Salvia R, Manfredi R, Pozzi Mucelli R, Bassi C.

Eur Radiol. 2018 Oct;28(10):4265-4273. doi: 10.1007/s00330-018-5410-6. Epub 2018 Apr 20.

PMID:
29679211
13.

Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer.

Holyoake DLP, Warren DR, Hurt C, Aznar M, Partridge M, Mukherjee S, Hawkins MA.

Clin Oncol (R Coll Radiol). 2018 Jul;30(7):418-426. doi: 10.1016/j.clon.2018.02.067. Epub 2018 Mar 28.

PMID:
29602584
14.

Obstructive jaundice as primary presentation of a stage IIE Non-Hodgkin lymphoma: A decision making process between advanced lymphoma and locally advanced/metastatic pancreatic adenocarcinoma.

Blouhos K, Boulas KA, Paraskeva A, Kariotis I, Barettas N, Hatzigeorgiadis A.

Int J Surg Case Rep. 2018;44:226-229. doi: 10.1016/j.ijscr.2018.02.038. Epub 2018 Mar 7.

15.

Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy.

van Veldhuisen E, Vogel JA, Klompmaker S, Busch OR, van Laarhoven HWM, van Lienden KP, Wilmink JW, Marsman HA, Besselink MG.

HPB (Oxford). 2018 Jul;20(7):605-611. doi: 10.1016/j.hpb.2018.01.001. Epub 2018 Feb 21.

16.

A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer.

Shabason JE, Chen J, Apisarnthanarax S, Damjanov N, Giantonio B, Loaiza-Bonilla A, O'Dwyer PJ, O'Hara M, Reiss KA, Teitelbaum U, Wissel P, Drebin JA, Vollmer C, Kochman M, Mick R, Vergara N, Jhala N, Doucette A, Lukens JN, Plastaras JP, Metz JM, Ben-Josef E.

Cancer Chemother Pharmacol. 2018 Mar;81(3):609-614. doi: 10.1007/s00280-018-3519-6. Epub 2018 Jan 23.

PMID:
29362902
17.

Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma.

Quan K, Sutera P, Xu K, Bernard ME, Burton SA, Wegner RE, Zeh H, Bahary N, Stoller R, Heron DE.

Pract Radiat Oncol. 2018 Mar - Apr;8(2):95-106. doi: 10.1016/j.prro.2017.10.001. Epub 2017 Oct 7.

PMID:
29291966
18.

Locally advanced pancreatic cancer: An emerging entity.

O Kane GM, Knox JJ.

Curr Probl Cancer. 2018 Jan - Feb;42(1):12-25. doi: 10.1016/j.currproblcancer.2017.10.006. Epub 2017 Nov 16. Review.

PMID:
29153290
19.

Does lymphocyte-to-monocyte ratio before, during, or after definitive chemoradiation for locally advanced pancreatic cancer predict for clinical outcomes?

Giacomelli I, Scartoni D, Mohammadi H, Regine WF, Chuong MD.

J Gastrointest Oncol. 2017 Aug;8(4):721-727. doi: 10.21037/jgo.2017.06.14.

20.

The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland.

Grose D, McIntosh D, Jamieson N, Carter R, Dickson E, Chang D, Marashi H, Wilson C, Alfayez M, Kerr A, O'Donoghue R, Haskins L, Duthie F, McKay CJ, Graham J.

J Gastrointest Oncol. 2017 Aug;8(4):683-695. doi: 10.21037/jgo.2017.04.01.

Supplemental Content

Loading ...
Support Center